Does the media refer more to REGN or BNTX?

In the previous week, Regeneron Pharmaceuticals had 47 more articles in the media than BioNTech. MarketBeat recorded 67 mentions for Regeneron Pharmaceuticals and 20 mentions for BioNTech. Regeneron Pharmaceuticals' average media sentiment score of 1.09 beat BioNTech's score of 0.11 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 46 Very Positive mention(s) 2 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ARGX or BNTX?

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 15.07 $1.29B $26.04 39.29 BioNTech $3.25B 7.95 -$1.29B -$7.83 N/A

Is ARGX or BNTX more profitable?

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% BioNTech -63.54% -6.86% -6.00%

Does the media prefer ARGX or BNTX?

In the previous week, BioNTech had 3 more articles in the media than argenex. MarketBeat recorded 20 mentions for BioNTech and 17 mentions for argenex. argenex's average media sentiment score of 0.39 beat BioNTech's score of 0.11 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, BNTX or NTRA?

Natera has lower revenue, but higher earnings than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.95 -$1.29B -$7.83 N/A Natera $2.31B 20.39 -$208.16M -$1.36 N/A

Is BNTX or NTRA more profitable?

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Natera -7.11% -11.38% -7.87%

Does the media prefer BNTX or NTRA?

In the previous week, Natera had 27 more articles in the media than BioNTech. MarketBeat recorded 47 mentions for Natera and 20 mentions for BioNTech. Natera's average media sentiment score of 1.27 beat BioNTech's score of 0.11 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Neutral Natera 34 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer BNTX or RVMD?

In the previous week, Revolution Medicines had 45 more articles in the media than BioNTech. MarketBeat recorded 65 mentions for Revolution Medicines and 20 mentions for BioNTech. Revolution Medicines' average media sentiment score of 1.01 beat BioNTech's score of 0.11 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Neutral Revolution Medicines 36 Very Positive mention(s) 8 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Positive

Which has preferable valuation and earnings, BNTX or BIIB?

Biogen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.95 -$1.29B -$7.83 N/A Biogen $10.03B 3.22 $1.29B $5.65 38.67

Is BNTX or BIIB more profitable?

Biogen has a net margin of 8.32% compared to BioNTech's net margin of -63.54%. Biogen's return on equity of 11.18% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Biogen 8.32% 11.18% 6.88%

Does the media prefer BNTX or BIIB?

In the previous week, Biogen had 18 more articles in the media than BioNTech. MarketBeat recorded 38 mentions for Biogen and 20 mentions for BioNTech. Biogen's average media sentiment score of 1.25 beat BioNTech's score of 0.11 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Neutral Biogen 28 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

BioNTech (BNTX) Competitors

$102.07 -9.33 (-8.38%)

As of 04:00 PM Eastern

Compare

BNTX vs. REGN, ARGX, NTRA, RVMD, and BIIB

Should you buy BioNTech stock or one of its competitors? BioNTech's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), and Biogen (BIIB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioNTech compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Regeneron Pharmaceuticals had 47 more articles in the media than BioNTech. MarketBeat recorded 67 mentions for Regeneron Pharmaceuticals and 20 mentions for BioNTech. Regeneron Pharmaceuticals' average media sentiment score of 1.09 beat BioNTech's score of 0.11 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	46 Very Positive mention(s)	2 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Neutral

Regeneron Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals presently has a consensus target price of $800.36, indicating a potential upside of 0.78%. BioNTech has a consensus target price of $127.81, indicating a potential upside of 25.22%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.60
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Regeneron Pharmaceuticals has a net margin of 27.86% compared to BioNTech's net margin of -63.54%. Regeneron Pharmaceuticals' return on equity of 13.47% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
BioNTech	-63.54%	-6.86%	-6.00%

Regeneron Pharmaceuticals has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.70	$4.50B	$40.46	19.63
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A

Summary

Regeneron Pharmaceuticals beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does BioNTech compare to argenex?

argenex (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	15.07	$1.29B	$26.04	39.29
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A

argenex presently has a consensus target price of $1,157.50, suggesting a potential upside of 13.12%. BioNTech has a consensus target price of $127.81, suggesting a potential upside of 25.22%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, BioNTech had 3 more articles in the media than argenex. MarketBeat recorded 20 mentions for BioNTech and 17 mentions for argenex. argenex's average media sentiment score of 0.39 beat BioNTech's score of 0.11 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Neutral

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

60.3% of argenex shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

argenex beats BioNTech on 13 of the 17 factors compared between the two stocks.

How does BioNTech compare to Natera?

BioNTech (NASDAQ:BNTX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Natera	-7.11%	-11.38%	-7.87%

BioNTech presently has a consensus price target of $127.81, suggesting a potential upside of 25.22%. Natera has a consensus price target of $319.38, suggesting a potential downside of 2.11%. Given BioNTech's higher probable upside, research analysts plainly believe BioNTech is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Natera has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

Natera has lower revenue, but higher earnings than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A
Natera	$2.31B	20.39	-$208.16M	-$1.36	N/A

In the previous week, Natera had 27 more articles in the media than BioNTech. MarketBeat recorded 47 mentions for Natera and 20 mentions for BioNTech. Natera's average media sentiment score of 1.27 beat BioNTech's score of 0.11 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Neutral
Natera	34 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Natera beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

BioNTech (NASDAQ:BNTX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Revolution Medicines has lower revenue, but higher earnings than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A
Revolution Medicines	$11.58M	3,847.75	-$1.13B	-$8.82	N/A

In the previous week, Revolution Medicines had 45 more articles in the media than BioNTech. MarketBeat recorded 65 mentions for Revolution Medicines and 20 mentions for BioNTech. Revolution Medicines' average media sentiment score of 1.01 beat BioNTech's score of 0.11 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Neutral
Revolution Medicines	36 Very Positive mention(s)	8 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	4 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioNTech currently has a consensus target price of $127.81, suggesting a potential upside of 25.22%. Revolution Medicines has a consensus target price of $198.89, suggesting a potential downside of 4.32%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

BioNTech has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Revolution Medicines	N/A	-88.20%	-57.85%

Summary

Revolution Medicines beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does BioNTech compare to Biogen?

BioNTech (NASDAQ:BNTX) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to BioNTech's net margin of -63.54%. Biogen's return on equity of 11.18% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Biogen	8.32%	11.18%	6.88%

BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

BioNTech presently has a consensus price target of $127.81, suggesting a potential upside of 25.22%. Biogen has a consensus price target of $227.79, suggesting a potential upside of 4.25%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts clearly believe BioNTech is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Biogen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.95	-$1.29B	-$7.83	N/A
Biogen	$10.03B	3.22	$1.29B	$5.65	38.67

In the previous week, Biogen had 18 more articles in the media than BioNTech. MarketBeat recorded 38 mentions for Biogen and 20 mentions for BioNTech. Biogen's average media sentiment score of 1.25 beat BioNTech's score of 0.11 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Neutral
Biogen	28 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats BioNTech on 11 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.17B	$4.02B	$7.24B	$12.93B
Dividend Yield	N/A	3.60%	2.54%	10.96%
P/E Ratio	-13.04	11.56	271.21	25.38
Price / Sales	7.95	1,346.04	623.95	92.16
Price / Cash	83.44	110.59	79.29	54.21
Price / Book	1.25	16.50	12.95	6.14
Net Income	-$1.29B	-$22.76M	$3.46B	$347.93M
7 Day Performance	-12.44%	-0.19%	-0.16%	-0.77%
1 Month Performance	10.41%	10.74%	7.32%	3.80%
1 Year Performance	0.14%	53.31%	23.87%	14.69%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	3.5083 of 5 stars	$102.07 -8.4%	$127.81 +25.2%	+8.1%	$28.17B	$3.25B	N/A	7,807	Trending News Options Volume Gap Down
REGN Regeneron Pharmaceuticals	4.3208 of 5 stars	$805.93 +0.3%	$801.70 -0.5%	+37.6%	$82.72B	$14.34B	19.92	15,410	Trending News
ARGX argenex	4.3266 of 5 stars	$987.84 +16.0%	$1,072.72 +8.6%	+49.6%	$53.26B	$4.25B	37.94	1,863	Analyst Upgrade High Trading Volume
NTRA Natera	2.6776 of 5 stars	$314.18 +1.4%	$319.38 +1.7%	+107.7%	$44.67B	$2.31B	N/A	6,140	Insider Trade
RVMD Revolution Medicines	2.5377 of 5 stars	$212.00 +4.1%	$161.79 -23.7%	+481.4%	$43.66B	$11.58M	N/A	250	Trending News Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. REGN, ARGX, NTRA, RVMD, and BIIB

How does BioNTech compare to Regeneron Pharmaceuticals?

Summary

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Natera?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

How does BioNTech compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. REGN, ARGX, NTRA, RVMD, and BIIB

How does BioNTech compare to Regeneron Pharmaceuticals?

Does the media refer more to REGN or BNTX?

Which has more risk and volatility, REGN or BNTX?

Do institutionals & insiders believe in REGN or BNTX?

Do analysts rate REGN or BNTX?

Is REGN or BNTX more profitable?

Which has higher earnings & valuation, REGN or BNTX?

Summary

How does BioNTech compare to argenex?

Which has preferable earnings & valuation, ARGX or BNTX?

Do analysts rate ARGX or BNTX?

Does the media prefer ARGX or BNTX?

Which has more risk & volatility, ARGX or BNTX?

Do insiders and institutionals hold more shares of ARGX or BNTX?

Is ARGX or BNTX more profitable?

Summary

How does BioNTech compare to Natera?

Is BNTX or NTRA more profitable?

Do analysts rate BNTX or NTRA?

Which has more volatility & risk, BNTX or NTRA?

Which has stronger valuation & earnings, BNTX or NTRA?

Does the media prefer BNTX or NTRA?

Do institutionals & insiders hold more shares of BNTX or NTRA?

Summary

How does BioNTech compare to Revolution Medicines?

Which has better earnings and valuation, BNTX or RVMD?

Does the media prefer BNTX or RVMD?

Do institutionals and insiders hold more shares of BNTX or RVMD?

Do analysts recommend BNTX or RVMD?

Which has more volatility and risk, BNTX or RVMD?

Is BNTX or RVMD more profitable?

Summary

How does BioNTech compare to Biogen?

Do insiders and institutionals hold more shares of BNTX or BIIB?

Is BNTX or BIIB more profitable?

Which has more risk & volatility, BNTX or BIIB?

Do analysts recommend BNTX or BIIB?

Which has preferable valuation and earnings, BNTX or BIIB?

Does the media prefer BNTX or BIIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools